2-methyl-2,3-diphenylpropanamide | 681153-30-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 2-methyl-2,3-diphenylpropanamide
• 英文别名: 2-methyl-2,3-diphenyl-propionic acid amide；2-Methyl-2,3-diphenyl-propionsaeure-amid
• CAS: 681153-30-0
• 化学式: C₁₆H₁₇NO
• 分子量: 239.317
• InChiKey: BUINOFINHPSFTL-UHFFFAOYSA-N

物化性质

• 熔点：
  133 °C
• 沸点：
  407.1±34.0 °C(Predicted)
• 密度：
  1.099±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-methyl-2,3-diphenylpropanamide 在 alkaline aqueous potassium hypobromite 作用下， 生成 1,2-二苯基丙烷-2-胺
  参考文献：
  名称：

  Mentzer; Chopin, Bulletin de la Societe Chimique de France, 1948, p. 586,588

  摘要：

  DOI：
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 硫酸 作用下， 生成 2-methyl-2,3-diphenylpropanamide
  参考文献：
  名称：

  Levy; Tabart, Bulletin de la Societe Chimique de France, 1931, vol. <4> 49, p. 1782,1786

  摘要：

  DOI：

文献信息

• [EN] COMPOUNDS AND METHODS<br/>[FR] COMPOSÉS ET MÉTHODES
  申请人：TEMPERO PHARMACEUTICALS INC

  公开号：WO2013019682A1

  公开（公告）日：2013-02-07

  The present invention relates to novel retinoid-related orphan receptor gamma (RORγ) modulators and their use in the treatment of diseases mediated by RORy.

  本发明涉及新型视黄醛酸相关孤儿受体γ（RORγ）调节剂及其在治疗由RORγ介导的疾病中的应用。
• 2-SULFINYL- AND 2-SULFONYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS
  申请人：Albrecht Wolfgang

  公开号：US20100273833A1

  公开（公告）日：2010-10-28

  The invention relates to 2-sulfinyl- or 2-sulfonyl-substituted imidazole derivatives of the formula (I) in which the radicals R 1 , R 2 , R 3 and R 4 have the meaning indicated in the description. The compounds of the invention have an immunomodulating and/or cytokine release-inhibiting effect and are therefore suitable for the treatment of disorders associated with an impairment of the immune system.

  本发明涉及式(I)的2-亚磺酰基或2-磺酰基取代的咪唑衍生物，其中基团R1、R2、R3和R4的含义如说明书所示。本发明的化合物具有免疫调节和/或细胞因子释放抑制作用，因此适用于治疗与免疫系统损伤有关的疾病。
• Platinum-Catalyzed Selective Hydration of Hindered Nitriles and Nitriles with Acid- or Base-Sensitive Groups
  作者：Xiao-bin Jiang、Adriaan J. Minnaard、Ben L. Feringa、Johannes G. de Vries

  DOI：10.1021/jo035487j

  日期：2004.4.1

  Hindered tertiary nitriles can be hydrolyzed under neutral and mild conditions to the corresponding amides using platinum(II) catalysts with dimethylphosphine oxide or other secondary phosphine oxides (SPOs, phosphinous acids) as ligands. We have found that this procedure also works well for nitriles with acid- or base-sensitive groups, which is unprecedented in terms of yield and selectivity. The catalyst loading can be as low as 0.5 mol %. Amides are isolated as the only product in high yield, and no further hydrolysis to the corresponding acids takes place. Reactions are carried out at 80 degreesC but take place even at room temperature. When enantiopure secondary phosphine oxide ligands are used in the hydrolysis of racemic nitriles, no kinetic resolution is observed, presumably due to racemization of the ligand during the reaction.
• COMPOUNDS AND METHODS
  申请人：Tempero Pharmaceuticals, Inc.

  公开号：EP2736330A1

  公开（公告）日：2014-06-04
• [EN] 2-SULFINYL- AND 2-SULFONYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS<br/>[FR] DÉRIVÉS D'IMIDAZOLE DE 2-SULFINYLE ET DE 2-SULFONYLE ET LEUR UTILISATION COMME INHIBITEURS DE CYTOKINES
  申请人：MERCKLE GMBH

  公开号：WO2006089798A1

  公开（公告）日：2006-08-31

  [EN] The invention relates to 2-sulfinyl- or 2-sulfonyl-substituted imidazole derivatives of the formula (I) in which the radicals R¹, R², R³ and R⁴ have the meaning indicated in the description. The compounds of the invention have an immunomodulating and/or cytokine release-inhibiting effect and are therefore suitable for the treatment of disorders associated with an impairment of the immune system.
  [FR] La présente invention concerne des dérivés d'imidazole de 2-sulfinyle et de 2-sulfonyle de la formule (I) dans laquelle les radicaux R¹, R², R³ et R⁴ possèdent la signification indiquée dans la description. Les composés de l'invention présentent un effet immunomodulateur et/ou d'inhibition de libération des cytokines et, par conséquent, sont appropriés pour le traitement de désordres associés aux troubles du système immunitaire.